Med. praxi. 2010;7(2):69-73

Specifics of Peripheral Vascular Disease by the diabetics

MUDr.Jarmila Indráková
I. interní klinika a II. chirurgická klinika LF UP a FN Olomouc

Peripheral Vascular Disease (PVD) affects estimatedly up to 20 % of the patients over 70 years. In its less advanced stages (stage I and II of the

Fontain classification) is chiefly a predictor of increased cardiovascular mortality due to a high probability of collateral ischemic heart and

brain disease. The more advanced stages of the disease limit the prognostically ill person significantly and they principally threaten the

quality of life, not only by the possibly amputation of the limb. There is 5 times more risk of PVD and possibility of gangrene 20 times

more in diabetic patients than in nondiabetic patiens. Incidence of PVD in population of diabetic patiens is almoust 30 %. Approximately

40–60 % of untraumatic amputations is provided in diabetic pationts. Diabetic foot syndrom has up to 6 % of patients with diabetes. That

is why the good compensation of diabetes is implied. Pharmacotheraphy is necessary – antiplatelet drugs, hypolipidemics, ACE inhibitors

and vasoactive drugs. The prostaglandines are reserved for the critical limb ischemia. As for the non pharmacologic means intensive

rehabilitation, good care of feet or diabetic footwear is required. In the cases of significant manifestations of the disease (stage III and IV

of the Fontain classification) the revascularisation, e. g. percutaneous transluminal angioplasty or surgical operations (endarterectomy,

bypasses) is unambiguously preferred.

Keywords: peripheral arthery disease, diabetes mellitus, atherosclerosis, diabetic foot

Published: April 22, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Indráková J. Specifics of Peripheral Vascular Disease by the diabetics. Med. praxi. 2010;7(2):69-73.
Download citation

References

  1. Newman AB, Shemanski L, Manolio TA, et al. Mortality over four years in SHEP participants with a low ancle-arm index. J Am Geriatr Soc 1997; 45: 472-478. Go to original source... Go to PubMed...
  2. Mezinárodní pracovní skupina pro syndrom diabetické nohy. Syndrom diabetické nohy. Mezinárodní konsenzus. České vydání: Ed. A. Jirkovská. Praha: Galén, 2000.
  3. Jirkovská A, a kol. Syndrom diabetické nohy. Týmová péče o pacienty. Maxdorf, 2006.
  4. Jirkovská A. Diabetická noha. In: Praktická diabetologie. 2. vydání, Ed. V. Bartoš, T. Pelikánová. Praha: Maxdorf, 2000: 305-325.
  5. Willigendael EM, TeijinkJA, Bartelink ML, Peters RJ, Buller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42(1): 67-74. Go to original source... Go to PubMed...
  6. Selvin E, Erlinger TP. Prevalence of and risc factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110(6): 738-743. Go to original source... Go to PubMed...
  7. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33, S1-S70 (2007). Go to original source... Go to PubMed...
  8. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107(5): 753-756. Go to original source... Go to PubMed...
  9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-1278. Go to original source... Go to PubMed...
  10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 22: 360-367.
  11. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33: S1-S70 (2007). Go to original source... Go to PubMed...
  12. ADA. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26(12): 3333-3341. Go to original source... Go to PubMed...
  13. Normandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massibenedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279-1289. Go to original source... Go to PubMed...
  14. Kieffer E, Bahnini A, Mouren X, et al. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001; 20: 58-65. Go to PubMed...
  15. D´Hodge D, Lehert P, Clement DL, et al. Naftidrofuryl in quality of life (NIQOL): a Belgian study. Int Angiol 2001; 20: 288-294. Go to PubMed...
  16. Lievre M, Morand S, Besse B, Fiessinger J, Boissel J. Oral beraprost sodium, a prostaglandin I (2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102(4): 426-431. Go to original source... Go to PubMed...
  17. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86. Go to PubMed...
  18. Howard PA. Aspirin Resistance. Ann Pharmacother 2002; 36: 1620-1624. Go to original source... Go to PubMed...
  19. De Schryver EL, et al. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. 2003; 1: CD001820. Go to original source... Go to PubMed...
  20. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35: 413-421. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.